Innovations in ovarian cancer treatment: PARP inhibitors
Improving pathways for the genetic testing of breast and ovarian cancer
Genetic testing for breast and ovarian cancer: tackling the challenges to availability
How can germline mutations distinguish risk for lethal and indolent prostate cancer?
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer